Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain

Authors: Asuncion Diaz, Mercedes Diez, Maria Jose Bleda, Mikel Aldamiz, Miguel Camafort, Xabier Camino, Concepcion Cepeda, Asuncion Costa, Oscar Ferrero, Paloma Geijo, Jose Antonio Iribarren, Santiago Moreno, Maria Elena Moreno, Pablo Labarga, Javier Pinilla, Joseba Portu, Federico Pulido, Carmen Rosa, Juan Miguel Santamaría, Mauricio Telenti, Luis Trapiella, Monica Trastoy, Pompeyo Viciana

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion.

Methods

Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI).

Results

A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9).

Conclusions

A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Diez M, Huerta C, Moreno T, Caloto T, Guerra D, Pozo F, Alcaide J, Castells C, Cardenal JI, Domínguez A, Gayoso P, Gutiérrez G, López MJ, Muñoz F, Navarro C, Picó M, Quirós JR, Robles F, Sánchez JM, Vanaclocha H, Vega T, Multicentre Project for Tuberculosis Research (MPTR) Study Group: Tuberculosis in Spain: epidemiological pattern and clinical practice. Int J Tuberc Lung Dis. 2002, 6: 295-300.PubMed Diez M, Huerta C, Moreno T, Caloto T, Guerra D, Pozo F, Alcaide J, Castells C, Cardenal JI, Domínguez A, Gayoso P, Gutiérrez G, López MJ, Muñoz F, Navarro C, Picó M, Quirós JR, Robles F, Sánchez JM, Vanaclocha H, Vega T, Multicentre Project for Tuberculosis Research (MPTR) Study Group: Tuberculosis in Spain: epidemiological pattern and clinical practice. Int J Tuberc Lung Dis. 2002, 6: 295-300.PubMed
2.
go back to reference Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, Alastrue I, Belda J, Tor J, Pérez-Hoyos S, Del Amo J, Spanish Multicenter Study Group of Seroconverters (GEMES): Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007, 21: 2521-2527. 10.1097/QAD.0b013e3282f1c933.CrossRefPubMed Muga R, Ferreros I, Langohr K, de Olalla PG, Del Romero J, Quintana M, Alastrue I, Belda J, Tor J, Pérez-Hoyos S, Del Amo J, Spanish Multicenter Study Group of Seroconverters (GEMES): Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. AIDS. 2007, 21: 2521-2527. 10.1097/QAD.0b013e3282f1c933.CrossRefPubMed
3.
go back to reference Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B: The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007, 21: 1441-1448. 10.1097/QAD.0b013e328216f441.CrossRefPubMedPubMedCentral Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B: The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007, 21: 1441-1448. 10.1097/QAD.0b013e328216f441.CrossRefPubMedPubMedCentral
4.
go back to reference Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA, Antiretroviral Therapy Cohort Collaboration: Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005, 41: 1772-1782. 10.1086/498315.CrossRefPubMed Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA, Antiretroviral Therapy Cohort Collaboration: Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005, 41: 1772-1782. 10.1086/498315.CrossRefPubMed
5.
go back to reference Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H, Swiss HIV Cohort Study: Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007, 44: 94-102. 10.1086/510080.CrossRefPubMed Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H, Swiss HIV Cohort Study: Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007, 44: 94-102. 10.1086/510080.CrossRefPubMed
6.
go back to reference Woldehanna S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004, 1: CD000171-PubMed Woldehanna S, Volmink J: Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004, 1: CD000171-PubMed
7.
go back to reference Churchyard GJ, Scano F, Grant AD, Chaisson RE: Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis. 2007, 196 (Suppl 1): S52-62. 10.1086/518662.CrossRefPubMed Churchyard GJ, Scano F, Grant AD, Chaisson RE: Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis. 2007, 196 (Suppl 1): S52-62. 10.1086/518662.CrossRefPubMed
8.
go back to reference Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J: Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007, 24: e238-10.1371/journal.pmed.0040238.CrossRef Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J: Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007, 24: e238-10.1371/journal.pmed.0040238.CrossRef
9.
go back to reference Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008, 12: 1235-1254.PubMed Hirsch-Moverman Y, Daftary A, Franks J, Colson PW: Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008, 12: 1235-1254.PubMed
10.
go back to reference Antonucci G, Girardi E, Raviglione M, Vanacore P, Angarano G, Chirianni A, Pagano G, Suter F, Lauria FN, Ippolito G: Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. GISTA (Gruppo Italiano di Studio Tubercolosi e AIDS). Eur Respir J. 2001, 18: 369-375. 10.1183/09031936.01.00087901.CrossRefPubMed Antonucci G, Girardi E, Raviglione M, Vanacore P, Angarano G, Chirianni A, Pagano G, Suter F, Lauria FN, Ippolito G: Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. GISTA (Gruppo Italiano di Studio Tubercolosi e AIDS). Eur Respir J. 2001, 18: 369-375. 10.1183/09031936.01.00087901.CrossRefPubMed
11.
go back to reference Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P: Factores asociados a la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos [Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. Enferm Infecc Microbiol Clin. 2010, 28: 215-21. 10.1016/j.eimc.2009.06.008.CrossRefPubMed Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P: Factores asociados a la no realización de la prueba de la tuberculina en una cohorte de pacientes VIH positivos [Factors related to non-prescription of tuberculin skin testing in a cohort of HIV-infected people]. Enferm Infecc Microbiol Clin. 2010, 28: 215-21. 10.1016/j.eimc.2009.06.008.CrossRefPubMed
12.
go back to reference Diez M, Diaz A, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaria JM, Telenti M, Trapiella L, Trastoy M, Viciana P: Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis. 2007, 11: 1196-1202.PubMed Diez M, Diaz A, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaria JM, Telenti M, Trapiella L, Trastoy M, Viciana P: Prevalence of M. tuberculosis infection and tuberculosis disease among HIV-infected people in Spain. Int J Tuberc Lung Dis. 2007, 11: 1196-1202.PubMed
13.
go back to reference Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E: Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida [Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan recommendations]. Enferm Infecc Microbiol Clin. 2004, 22: 160-176. 10.1157/13058025.PubMed Berenguer J, Laguna F, López-Aldeguer J, Moreno S, Arribas JR, Arrizabalaga J, Baraia J, Casado JL, Cosín J, Polo R, González-García J, Iribarren JA, Kindelán JM, López-Bernaldo de Quirós JC, López-Vélez R, Lorenzo JF, Lozano F, Mallolas J, Miró JM, Pulido F, Ribera E: Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH. Recomendaciones de GESIDA/Plan Nacional sobre el Sida [Prevention of opportunistic infections in adult and adolescent patients with HIV infection. GESIDA/National AIDS Plan recommendations]. Enferm Infecc Microbiol Clin. 2004, 22: 160-176. 10.1157/13058025.PubMed
14.
go back to reference Ministerio de Sanidad y Consumo. Fondo de Investigación Sanitaria: Consenso nacional para el control de la tuberculosis [National consensus on the control of tuberculosis in Spain]. Med Clin (Barc). 1992, 98: 24-31. Ministerio de Sanidad y Consumo. Fondo de Investigación Sanitaria: Consenso nacional para el control de la tuberculosis [National consensus on the control of tuberculosis in Spain]. Med Clin (Barc). 1992, 98: 24-31.
15.
go back to reference Hosmer DW, Lemeshow S: Applied Logistic Regression. 2000, New York: Wiley-Interscience, 2CrossRef Hosmer DW, Lemeshow S: Applied Logistic Regression. 2000, New York: Wiley-Interscience, 2CrossRef
16.
go back to reference McCullagh P, Nelder J: Generalized Linear Models. 1989, London: Chapman and Hall, 2CrossRef McCullagh P, Nelder J: Generalized Linear Models. 1989, London: Chapman and Hall, 2CrossRef
17.
go back to reference Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D: Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection. The 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest. 2002, 122: 1292-1298. 10.1378/chest.122.4.1292.CrossRefPubMed Narita M, Kellman M, Franchini DL, McMillan ME, Hollender ES, Ashkin D: Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection. The 2-year experience of a comprehensive community-based program in Broward County, Florida. Chest. 2002, 122: 1292-1298. 10.1378/chest.122.4.1292.CrossRefPubMed
18.
go back to reference Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, Rodríguez Zapata M, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch JJ: Evaluación de dos pautas de quimioprofilaxis tuberculosa en pacientes infectados por el virus de la inmunodeficiencia humana [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus]. Med Clin (Barc). 2000, 115: 161-165.CrossRef Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, Rodríguez Zapata M, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch JJ: Evaluación de dos pautas de quimioprofilaxis tuberculosa en pacientes infectados por el virus de la inmunodeficiencia humana [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus]. Med Clin (Barc). 2000, 115: 161-165.CrossRef
19.
go back to reference Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, Díez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernández JJ, Márquez M, Kindelán JM, Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI): Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin. 2007, 25: 305-310. 10.1157/13102265.CrossRefPubMed Rivero A, López-Cortés L, Castillo R, Verdejo J, García MA, Martínez-Marcos FJ, Díez F, Escribano JC, Canueto J, Lozano F, Pasquau J, Hernández JJ, Márquez M, Kindelán JM, Grupo Andaluz para el estudio de las Enfermedades Infecciosas (GAEI): Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH [Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients]. Enferm Infecc Microbiol Clin. 2007, 25: 305-310. 10.1157/13102265.CrossRefPubMed
20.
go back to reference Pina-Gutiérrez JM, Ferrer-Traid A, Arias C, Sala-Farré MR, López-Sanmartín JL: Cumplimiento y efectividad del tratamiento de la infección tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes [Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients]. Med Clin (Barc). 2008, 130: 165-171. 10.1157/13116320.CrossRef Pina-Gutiérrez JM, Ferrer-Traid A, Arias C, Sala-Farré MR, López-Sanmartín JL: Cumplimiento y efectividad del tratamiento de la infección tuberculosa con isoniazida durante 9 meses en una cohorte de 755 pacientes [Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients]. Med Clin (Barc). 2008, 130: 165-171. 10.1157/13116320.CrossRef
21.
go back to reference Sackoff JE, Torian LV, Frieden TR, Brudney KF, Menzies IB: Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City. AIDS. 1998, 12: 2017-2023. 10.1097/00002030-199815000-00013.CrossRefPubMed Sackoff JE, Torian LV, Frieden TR, Brudney KF, Menzies IB: Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City. AIDS. 1998, 12: 2017-2023. 10.1097/00002030-199815000-00013.CrossRefPubMed
22.
go back to reference Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ: Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006, 174: 717-721. 10.1164/rccm.200510-1667OC.CrossRefPubMed Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ: Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006, 174: 717-721. 10.1164/rccm.200510-1667OC.CrossRefPubMed
23.
go back to reference García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRefPubMed García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRefPubMed
24.
go back to reference Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS: Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS. 1999, 13: 2069-2074. 10.1097/00002030-199910220-00009.CrossRefPubMed Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS: Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS. 1999, 13: 2069-2074. 10.1097/00002030-199910220-00009.CrossRefPubMed
25.
go back to reference Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boix V, Grupo de Estudio Protocolo-INH: Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniacida [Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]. Enferm Infecc Microbiol Clin. 2003, 21: 293-295. 10.1157/13048576.CrossRefPubMed Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boix V, Grupo de Estudio Protocolo-INH: Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniacida [Directly observed treatment of latent tuberculosis infection: comparative study of two isoniazid regimens]. Enferm Infecc Microbiol Clin. 2003, 21: 293-295. 10.1157/13048576.CrossRefPubMed
26.
go back to reference Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998, 351: 786-792. 10.1016/S0140-6736(97)06532-X.CrossRefPubMed Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE: Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet. 1998, 351: 786-792. 10.1016/S0140-6736(97)06532-X.CrossRefPubMed
27.
go back to reference Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KP, Porter JD: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998, 12: 2447-2457. 10.1097/00002030-199818000-00014.CrossRefPubMed Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KP, Porter JD: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998, 12: 2447-2457. 10.1097/00002030-199818000-00014.CrossRefPubMed
28.
go back to reference Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ: Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000, 283: 1445-1450. 10.1001/jama.283.11.1445.CrossRefPubMed Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ: Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000, 283: 1445-1450. 10.1001/jama.283.11.1445.CrossRefPubMed
29.
go back to reference Centers for Disease Control and Prevention (CDC); American Thoracic Society: Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003, 52: 735-739. Centers for Disease Control and Prevention (CDC); American Thoracic Society: Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003, 52: 735-739.
30.
go back to reference Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR, Tuberculosis Epidemiologic Studies Cosortium: The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006, 173: 927-931. 10.1164/rccm.200510-1563OC.CrossRefPubMed Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR, Tuberculosis Epidemiologic Studies Cosortium: The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006, 173: 927-931. 10.1164/rccm.200510-1563OC.CrossRefPubMed
Metadata
Title
Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain
Authors
Asuncion Diaz
Mercedes Diez
Maria Jose Bleda
Mikel Aldamiz
Miguel Camafort
Xabier Camino
Concepcion Cepeda
Asuncion Costa
Oscar Ferrero
Paloma Geijo
Jose Antonio Iribarren
Santiago Moreno
Maria Elena Moreno
Pablo Labarga
Javier Pinilla
Joseba Portu
Federico Pulido
Carmen Rosa
Juan Miguel Santamaría
Mauricio Telenti
Luis Trapiella
Monica Trastoy
Pompeyo Viciana
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-267

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.